Generic Oncology Drugs Market Report
RA00763
Generic Oncology Drugs Market, by Molecule (Large Molecule, Small Molecule), Route Of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2020-2027
The global generic oncology drugs market is estimated to surpass $37,683.4 million by 2027, exhibiting a CAGR of 6.6% from 2020 to 2027.
The report provides all-inclusive analysis of global generic oncology drugs market with comprehensive study of the various facets of the market including market dynamics, major segments and regions, top leading players, and competitive landscape.
The report emphasizes current market scenario and future trends of the global generic oncology drugs market which gleaned from the impact of various market dynamics such as drivers, challenges & restraints, lucrative opportunities. The report also highlights the key forces that are shaping the market. Besides, the report provides Porter’s five forces analysis which precisely underlines the impact of key forces on the global generic oncology drugs market.
In addition, the report provides market size and forecast scrutinizing global generic oncology drugs market through different segments. The report highlights the geographical market analysis of these segments and each segment is thoroughly studied at regional as well as country level to get clearer picture of the global generic oncology drugs market. In the report, the global generic oncology drugs market is divided into four major regions including North America, Europe, Asia-Pacific, and LAMEA. These regions are further divided into major countries to cover generic oncology drugs market landscape in respective regions.
Furthermore, competitive scenario of the global generic oncology drugs market is covered in the report. Major players functioning in the global generic oncology drugs market are also studied to understand their position and competitive strengths in the industry. The major company profiles covered in the report include various company’s datum such as brief overview, recent financials, main executives, adoption of key growth strategies, novel advancements or initiatives to sustain and expand their position in the global generic oncology drugs market, and others.
Research Methodology
Research Dive offers its clients extensive research and analysis gleaned from wide variety of factual inputs that largely includes interview with participants of the industry, reliable data & statistics, and regional intelligence. The in-house experts of the industry play a crucial role in designing analytic tools and models, tailor-made to the requests of an industry segment. The data and statistics are sterilized with these analytical tools and models, which enhances the accuracy of our advice and recommendations.
This research report is delivered by Research Dive by conducting long hours of discussions and interviews, with a broad range of stakeholders, which includes upstream and downstream participants. Our analysts have performed a mix of primary and secondary research for the market estimations and forecasts. A number of product type literatures, industry releases, annual reports, and other related documents of major participants of the industry have been reviewed, to better understand the global generic oncology drugs market scenario. The initial phase of our in-depth study, where we perform wide-range data mining, referring to proficient & verified data sources such as independent studies, medical journals, technical journals, releases by trade association, materials published by government & regulatory authorities, and other.
KEY MARKET BENEFITS
- This report is a compilation of detailed study, information, valid inputs from industry experts & industry participants across the value chain, and quantitative & qualitative assessment by analysts of the industry.
- The report provides a comprehensive analysis along with the current trends of market during the forecast period from 2019 to 2027 to identify & comprehend the prevailing opportunities and the strategic assessment of the global generic oncology drugs market growth.
- The report studies the market from 2019 to 2027 and maps the qualitative impact of several industry factors on market segments as well as geographies.
- The report provides market estimations and size which is based on in-depth analysis of recent & key developments in the generic oncology drugs market.
- The development strategies implemented by the key industry players are conscripted in the report to understand the competitive scenario of the global generic oncology drugs market.
KEY MARKET SEGMENTS
The market has been studied based on the following segments:
- Molecule: Large Molecule, Small Molecule
- Route Of Administration: Oral, Parenteral
- Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Region:
The global generic oncology drugs market is divided into North America, Europe, Asia Pacific, and LAMEA.
The above-mentioned regions are further dived in countries as follows:
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Saudi Arabia
- South Africa
- UAE
- Rest of LAMEA
KEY MARKET PLAYERS
The report covers the major players operating in the global generic oncology drugs market that focus on advancements & innovations and geographical expansion of product portfolios to obtain a competitive edge in the market space. The major players enlisted in the report include NATCO Pharma Limited, NATCO Pharma Limited, Mylan N.V., Celgene Corporation, …., and others.
The report summarizes various aspects of all these key players that include as follows:
1. Novartis AG
2. Aurobindo Pharma
3. Celgene Corporation
4. F. Hoffmann-La Roche Ltd
5. GlaxoSmithKline plc
6. Hikma Pharmaceuticals PLC
7. Lupin Pharmaceuticals
8. Merck & Company, Inc
9. Mylan N.V.
10. NATCO Pharma Limited
-
1. RESEARCH METHODOLOGY
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
-
2. REPORT SCOPE
2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on Global Generic Oncology Drugs Market
-
3. EXECUTIVE SUMMARY
-
4. MARKET OVERVIEW
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Environmental
4.7. Impact of COVID-19 on Generic Oncology Drugs Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
-
5. Generic Oncology Drugs Market, By Scale Of Operation
5.1. Overview
5.2 Large Molecule
5.2.1 Definition, key trends, growth factors, and opportunities
5.2.2 Market size analysis, by region, 2020-2027
5.2.3 Market share analysis, by country, 2020-2027
5.3 Small Molecule
5.3.1 Definition, key trends, growth factors, and opportunities
5.3.2 Market size analysis, by region, 2020-2027
5.3.3 Market share analysis, by country, 2020-2027
5.4 Research Dive Exclusive Insights
5.4.1 Market attractiveness
5.4.2 Competition heatmap
-
6. Generic Oncology Drugs Market, By Treatment
6.1. Overview
6.2 Oral
6.2.1 Definition, key trends, growth factors, and opportunities
6.2.2 Market size analysis, by region, 2020-2027
6.2.3 Market share analysis, by country, 2020-2027
6.3 Parenteral
6.3.1 Definition, key trends, growth factors, and opportunities
6.3.2 Market size analysis, by region, 2020-2027
6.3.3 Market share analysis, by country, 2020-2027
6.4 Research Dive Exclusive Insights
6.4.1 Market attractiveness
6.4.2 Competition heatmap
-
7. Generic Oncology Drugs Market, By Location
7.1. Overview
7.2 Hospital Pharmacy
7.2.1 Definition, key trends, growth factors, and opportunities
7.2.2 Market size analysis, by region, 2020-2027
7.2.3 Market share analysis, by country, 2020-2027
7.3 Retail Pharmacy
7.3.1 Definition, key trends, growth factors, and opportunities
7.3.2 Market size analysis, by region, 2020-2027
7.3.3 Market share analysis, by country, 2020-2027
7.4 Online Pharmacy
7.4.1 Definition, key trends, growth factors, and opportunities
7.4.2 Market size analysis, by region, 2020-2027
7.4.3 Market share analysis, by country, 2020-2027
7.5 Research Dive Exclusive Insights
7.5.1 Market attractiveness
7.5.2 Competition heatmap
8. Generic Oncology Drugs Market, By Region
8.1 North America
8.1.1 U.S
8.1.1.1 Market size analysis, By Scale of Operation, 2020-2027
8.1.1.2 Market size analysis, By Treatment, 2020-2027
8.1.1.3 Market size analysis, By Location, 2020-2027
8.1.2 Canada
8.1.2.1 Market size analysis, By Scale of Operation, 2020-2027
8.1.2.2 Market size analysis, By Treatment, 2020-2027
8.1.2.3 Market size analysis, By Location, 2020-2027
8.1.3 Mexico
8.1.3.1 Market size analysis, By Scale of Operation, 2020-2027
8.1.3.2 Market size analysis, By Treatment, 2020-2027
8.1.3.3 Market size analysis, By Location, 2020-2027
8.1.4 Research Dive Exclusive Insights
8.1.4.1 Market attractiveness
8.1.4.2 Competition heatmap
8.2 Europe
8.2.1 Germany
8.2.1.1 Market size analysis, By Scale of Operation, 2020-2027
8.2.1.2 Market size analysis, By Treatment, 2020-2027
8.2.1.3 Market size analysis, By Location, 2020-2027
8.2.2 UK
8.2.2.1 Market size analysis, By Scale of Operation, 2020-2027
8.2.2.2 Market size analysis, By Treatment, 2020-2027
8.2.2.3 Market size analysis, By Location, 2020-2027
8.2.3 France
8.2.3.1 Market size analysis, By Scale of Operation, 2020-2027
8.2.3.2 Market size analysis, By Treatment, 2020-2027
8.2.3.3 Market size analysis, By Location, 2020-2027
8.2.4 Spain
8.2.4.1 Market size analysis, By Scale of Operation, 2020-2027
8.2.4.2 Market size analysis, By Treatment, 2020-2027
8.2.4.3 Market size analysis, By Location, 2020-2027
8.2.5 Italy
8.2.5.1 Market size analysis, By Scale of Operation, 2020-2027
8.2.5.2 Market size analysis, By Treatment, 2020-2027
8.2.5.3 Market size analysis, By Location, 2020-2027
8.2.6 Rest of Europe
8.2.6.1 Market size analysis, By Scale of Operation, 2020-2027
8.2.6.2 Market size analysis, By Treatment, 2020-2027
8.2.6.3 Market size analysis, By Location, 2020-2027
8.2.7 Research Dive Exclusive Insights
8.2.7.1 Market attractiveness
8.2.7.2 Competition heatmap
8.3 Asia-Pacific
8.3.1 China
8.3.1.1 Market size analysis, By Scale of Operation, 2020-2027
8.3.1.2 Market size analysis, By Treatment, 2020-2027
8.3.1.3 Market size analysis, By Location, 2020-2027
8.3.2 Japan
8.3.2.1 Market size analysis, By Scale of Operation, 2020-2027
8.3.2.2 Market size analysis, By Treatment, 2020-2027
8.3.2.3 Market size analysis, By Location, 2020-2027
8.3.3 India
8.3.3.1 Market size analysis, By Scale of Operation, 2020-2027
8.3.3.2 Market size analysis, By Treatment, 2020-2027
8.3.3.3 Market size analysis, By Location, 2020-2027
8.3.4 Australia
8.3.4.1 Market size analysis, By Scale of Operation, 2020-2027
8.3.4.2 Market size analysis, By Treatment, 2020-2027
8.3.4.3 Market size analysis, By Location, 2020-2027
8.3.5 South Korea
8.3.5.1 Market size analysis, By Scale of Operation, 2020-2027
8.3.5.2 Market size analysis, By Treatment, 2020-2027
8.3.5.3 Market size analysis, By Location, 2020-2027
8.3.6 Rest of Asia-Pacific
8.3.6.1 Market size analysis, By Scale of Operation, 2020-2027
8.3.6.2 Market size analysis, By Treatment, 2020-2027
8.3.6.3 Market size analysis, By Location, 2020-2027
8.3.7 Research Dive Exclusive Insights
8.3.7.1 Market attractiveness
8.3.7.2 Competition heatmap
8.4 LAMEA
8.4.1 Brazil
8.4.1.1 Market size analysis, By Scale of Operation, 2020-2027
8.4.1.2 Market size analysis, By Treatment, 2020-2027
8.4.1.3 Market size analysis, By Location, 2020-2027
8.4.2 Saudi Arabia
8.4.2.1 Market size analysis, By Scale of Operation, 2020-2027
8.4.2.2 Market size analysis, By Treatment, 2020-2027
8.4.2.3 Market size analysis, By Location, 2020-2027
8.4.3 UAE
8.4.3.1 Market size analysis, By Scale of Operation, 2020-2027
8.4.3.2 Market size analysis, By Treatment, 2020-2027
8.4.3.3 Market size analysis, By Location, 2020-2027
8.4.4 South Africa
8.4.4.1 Market size analysis, By Scale of Operation, 2020-2027
8.4.4.2 Market size analysis, By Treatment, 2020-2027
8.4.4.3 Market size analysis, By Location, 2020-2027
8.4.5 Rest of LAMEA
8.4.5.1 Market size analysis, By Scale of Operation, 2020-2027
8.4.5.2 Market size analysis, By Treatment, 2020-2027
8.4.5.3 Market size analysis, By Location, 2020-2027
8.4.6 Research Dive Exclusive Insights
8.4.6.1 Market attractiveness
8.4.6.2 Competition heatmap
9. Competitive Landscape
9.1 Top winning strategies, 2020-2027
9.1.1 By strategy
9.1.2 By year
9.2 Strategic overview
9.3 Market share analysis, 2020-2027
10. Company Profiles
10.1 Novartis AG
10.1.1 Overview
10.1.2 Business segments
10.1.3 Product portfolio
10.1.4 Financial performance
10.1.5 Recent developments
10.1.6 SWOT analysis
10.2 Aurobindo Pharma
10.2.1 Overview
10.2.2 Business segments
10.2.3 Product portfolio
10.2.4 Financial performance
10.2.5 Recent developments
10.2.6 SWOT analysis
10.3 Celgene Corporation
10.3.1 Overview
10.3.2 Business segments
10.3.3 Product portfolio
10.3.4 Financial performance
10.3.5 Recent developments
10.3.6 SWOT analysis
10.4 F. Hoffmann-La Roche Ltd
10.4.1 Overview
10.4.2 Business segments
10.4.3 Product portfolio
10.4.4 Financial performance
10.4.5 Recent developments
10.4.6 SWOT analysis
10.5 GlaxoSmithKline plc
10.5.1 Overview
10.5.2 Business segments
10.5.3 Product portfolio
10.5.4 Financial performance
10.5.5 Recent developments
10.5.6 SWOT analysis
10.6 Hikma Pharmaceuticals PLC
10.6.1 Overview
10.6.2 Business segments
10.6.3 Product portfolio
10.6.4 Financial performance
10.6.5 Recent developments
10.6.6 SWOT analysis
10.7 Lupin Pharmaceuticals
10.7.1 Overview
10.7.2 Business segments
10.7.3 Product portfolio
10.7.4 Financial performance
10.7.5 Recent developments
10.7.6 SWOT analysis
10.8 Merck & Company, Inc
10.8.1 Overview
10.8.2 Business segments
10.8.3 Product portfolio
10.8.4 Financial performance
10.8.5 Recent developments
10.8.6 SWOT analysis
10.9 Mylan N.V.
10.9.1 Overview
10.9.2 Business segments
10.9.3 Product portfolio
10.9.4 Financial performance
10.9.5 Recent developments
10.9.6 SWOT analysis
10.10 NATCO Pharma Limited
10.10.1 Overview
10.10.2 Business segments
10.10.3 Product portfolio
10.10.4 Financial performance
10.10.5 Recent developments
10.10.6 SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
